Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Immuntherapie

  • Chapter
Kompendium Internistische Onkologie

  • 90 Accesses

Zusammenfassung

Immuntherapeutische Verfahren bei Patienten mit malignen Tumoren können in aktive und passive Ansätze unterteilt werden. Unter aktiver Immuntherapie versteht man den Versuch, das Immunsystem des Patienten unspezifisch oder spezifisch so zu modulieren, daß die zytotoxischen Effektormechanismen sich gegen den eigenen Tumor richten. Da Tumorpatienten häufig unter einer Immunsuppression leiden, die zu einer Beeinträchtigung der aktiven Immunantwort führen kann, wurden in den letzten Jahren zunehmend passive immuntherapeutische Prinzipien in der Therapie maligner Erkrankungen eingesetzt. Passive Immuntherapie beinhaltet den Transfer von Antikörpern oder spezifischen Immunzellen, die in der Lage sind, direkt oder indirekt eine Antitumorwirkung hervorzurufen. Der Begriff „adoptive Immuntherapie“ bezeichnet in diesem Zusammenhang üblicherweise die Übertragung von immunologischen Effektorzellen (Lymphozyten, Makrophagen).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Andreesen R, Scheibenbogen C, Brugger W et al. (1990) Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 50:7450–7456

    PubMed  CAS  Google Scholar 

  • Bar MH, Sznol M, Atkins MB, et al. (1990) Metastatic malignant melanoma treated with a combined bolus and continuous infusion interleukin-2 and lymphokine activated killer cells. J Clin Oncol 8:1138–1147

    PubMed  CAS  Google Scholar 

  • Bergmann L (1992) Immunmodulatoren in der Therapie gastrointestinaler Karzinome. In: Schmoll HJ, Meyer HJ, Wilke H, Pichlmayr R (Hrsg) Aktuelle Therapie gastrointestinaler Tumoren. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Dillman RO, Oldham RK, Barth NM, et al. (1991) Continuous Interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. Cancer 68:1–8

    Article  PubMed  CAS  Google Scholar 

  • Dutcher JP, Creekmore S, Weiss GR et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477–485

    PubMed  CAS  Google Scholar 

  • Fisher RI, Coltman CA, Doroshow JH et al. (1988) Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 108:518–523

    PubMed  CAS  Google Scholar 

  • Keilholz U, Schlag P, Tilgen W et al. (1992) Regional application of lymphokine activated killer cells can be superior to i. v. application. Cancer 69:2172–2175

    Article  PubMed  CAS  Google Scholar 

  • Keilholz U, Scheibenbogen C, Schlag P et al. (1994) Regional adoptive immunotherapy with IL-2 and LAK cells for liver metastases of malignant melanoma. Eur J Cancer (in press)

    Google Scholar 

  • Mathé G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M (1965) Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 25:1525–1531

    PubMed  Google Scholar 

  • Negrier S, Philip T, Stoter G et al. (1990) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma. A report of an European multicentre study. Europ J Cancer Clin Oncol [Suppl 3]:15–21

    Google Scholar 

  • Paciucci PA, Holland JF, Glidewell O et al. (1989) Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer. J Clin Oncol 7:869–878

    PubMed  CAS  Google Scholar 

  • Parkinson DR, Fisher RI, Rayner AA et al. (1990) Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8:1630–1636

    PubMed  CAS  Google Scholar 

  • Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100–106

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Packard BS, Aebersold PM et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676–1680

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC, Abersold PM, Linehan WM, Seipp CA, White D (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–485

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Aeberslod P, Cornetta K et al. (1990) Gene transfer into humans-immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578

    Article  PubMed  CAS  Google Scholar 

  • Weiss GR, Margolin K, Aronson FR et al. (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection IL-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10 (2):275–281

    PubMed  CAS  Google Scholar 

  • West WH, Tauer K, Yanelli JR et al. (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Cohen J (1993) Cancer vaccines get a shot in the arm. Research News. Science 262:841–843

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Linsley PS (1992) Costimulation of T cell growth. Curr Opinion Immunol 4:265–270

    Article  CAS  Google Scholar 

  • Schirrmacher V (1990) Krebsimpfung mit Tumorzellen. Spektrum der Wissenschaft 1:38–50

    Google Scholar 

  • Schirrmacher V (1993) Active specific immunotherapy (ASI) — a new modality of cancer treatment involving the patients own immune system. Onkologie 16:290–296

    Article  Google Scholar 

  • Schirrmacher V (1994) Guest Editorial: Biotherapy of cancer. Perspectives of immunotherapy and genetherapy. Cancer Res Clin Oncol (in press)

    Google Scholar 

  • Schirrmacher V (1995) Immuntherapie maligner Tumoren unter besonderer Berücksichtigung der aktiv-spezifischen Immuntherapie. Onkologie Aktuell — Diagnostik und Therapie (im Druck)

    Google Scholar 

  • Schirrmacher K, Schlag P, Liebrich W, Patel BT, Stoeck M (1993) Specific immunotherapy of colorectal carcinoma with Newcastle Disease Virus, modified autologous tumor cells prepaired from resected liver metastases. In: Bystyn JC, Ferroul S, Livingston P (eds) Ann NY Acad Sci 690:1–411

    Google Scholar 

  • Urban JL, Schreiber H (1992) Tumor antigens. Ann Rev Immunol 10:617–644

    Article  CAS  Google Scholar 

Literatur

  • Grossbard ML, Nadler LM (1993) Monoclonal antibody therapy for indolent lymphomas. Semin Oncol 20:118–135

    PubMed  CAS  Google Scholar 

  • Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863–878

    PubMed  CAS  Google Scholar 

  • Mellstedt H, Frödin JE, Masucci G, Ragnhammar P, Fagerberg J, Hjelm AL, Shetye J, Wersäll P, and Österborg A (1991) The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 18:462–477

    PubMed  CAS  Google Scholar 

  • Riethmüller G, Johnson JP (1992) Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 4:647–655

    Article  PubMed  Google Scholar 

  • Riethmüller G, Schneider-Gädicke E, Schlimok G et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343:1177–1183

    Article  PubMed  Google Scholar 

  • Winter G, Harris WJ (1993) Humanized antibodies. Immunol Today 14:243–246

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Amlot PL, Cunningham SD, Fay J, Newman J, Collins R, May R, McCarthy M, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624–2633

    PubMed  CAS  Google Scholar 

  • Bischof-Delaloye A, Delaloye B, Buchegger F, Gilgien W, Studer A, Curchod S, Givel JC, Mosimann F, Pettavel J, Mach JP (1989) Clinical value of immunoscintigraphy in colorectal carcinoma patients: A prospective study. J Nucl Med 30:1646–1656

    PubMed  CAS  Google Scholar 

  • Blumenthal, RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, Goldenberg DM (1992) Targeted Therapy of athymic mice bearing GW-39 human colonic cancer micrometastasis with 131-J-labeled monoclonal antibodies. Cancer Res 52:6036–6044

    PubMed  CAS  Google Scholar 

  • Buchegger F, P-legrin A, Delalaoye B, Bischof-Delaloye A, Mach JP (1990) Iodine-131-labeled Mab F2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted nude mice. J Nucl Med 31:1035–1044

    PubMed  CAS  Google Scholar 

  • Buchsbaum DJ, Langmuir VK, Wessels BW (1993) Experimental radioimmunotherapy. Med Phys 20:551–567

    Article  PubMed  CAS  Google Scholar 

  • DeNardo G, DeNardo SL, O’Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radioimmunotherapy of B-cell malignancies with 131-I-Lym-1. Cancer Res 50 [Suppl]:1014s–1016s

    PubMed  CAS  Google Scholar 

  • DeNardo SJ, DeNardo G, Richman CM (1992) Enhancement of clinical radioimmunotherapy for cancer and the role of cytokines. J Natl Cancer Inst 84:374–375

    Article  PubMed  CAS  Google Scholar 

  • Ehrlich P (1906) Collected studies in immunity. Wiley, New York

    Google Scholar 

  • Goldenberg DM, Goldenberg H, Sharkey RM, Higginbotham-Ford E, Lee RE, Swayne LC, Burger KA, Tsai D, Horowitz JA, Hall TC, Pinsky CM, Hansen HJ (1990) Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123-I or 99m-Tc. Cancer Res 50 [Suppl]:909s–921s

    PubMed  CAS  Google Scholar 

  • Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, Burger K, Swayne LC, Belisle E, Hansen HJ, Pinsky CM (1991) Targeting, dosimetric, and radioim-munotherapy of B-cell lymphomas with Iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9:548–564

    PubMed  CAS  Google Scholar 

  • Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H (1993) Medical applications of single-chain antibodies. Int Rev Immunol 10:195–217

    Article  PubMed  CAS  Google Scholar 

  • Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H (1993) Medical applications of single-chain antibodies. Int Rev Immunol 10:195–217

    Article  PubMed  CAS  Google Scholar 

  • Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL (1993) Radioimmunotherapy of B-cell lymphoma with 131-I-Anti-B1 (Anti-CD20) antibody. N Engl J Med 329:459–465

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ (1993) Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small cell lung cancer. Chest 103 [Suppl]:436s–439s.

    Article  PubMed  Google Scholar 

  • Mayforth RD, Quintns J (1990) Designer and catalytic antibodies. N Engl J Med 323:173–178

    Article  PubMed  CAS  Google Scholar 

  • Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I (1990) Radioimmunotherapy of human B-cell lymphoma with 90-Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50 [Suppl]:1022s–1028s

    PubMed  CAS  Google Scholar 

  • Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224

    Article  PubMed  CAS  Google Scholar 

  • Riva P, Arista A, Sturiale C, Moscatelli G, Tison V, Mariani M, Seccamani E, Lazzari S, Fagioli L, Franceschi G (1992) Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labeled antitenascin monoclonal antibody BC-2. Int J Cancer 51:7–13

    Article  PubMed  CAS  Google Scholar 

  • Rowlinson-Busza G, Epenetos AA (1992) Targeted delivery of biologic and other neoplastic agents. Curr Opin Oncol 4:1142–1148

    Article  PubMed  CAS  Google Scholar 

  • Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Scheinber DA (1993) Dose-escalation trial M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11:294–303

    PubMed  CAS  Google Scholar 

  • Waldmann TA (1991) Monoclonal antibodies in diagnosis and therapy. Science 252:1657–1662

    Article  PubMed  CAS  Google Scholar 

  • Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N, Carswell EA, Oettgen HF, Old LJ (1990) Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study of monoclonal antibody A33. J Clin Oncol 8:1894–1906

    PubMed  CAS  Google Scholar 

  • Winter G, Harris WJ (1993) Humanized antibodies. Immunol Today 14:243–246

    Article  PubMed  CAS  Google Scholar 

  • Wittig BM, Hach A, Hahn K, Meyer zum B-schenfelde KH, Dippold WG (1993) CEA-immunoscintigraphy with 99m-Technetium correlates with tumour cell differentiation in colorectal cancer. Eur J Cancer 29A:1327–1329

    Article  PubMed  CAS  Google Scholar 

  • Ychou M, Ricard M, Lumbroso J, Rougier P, Mach JP, Buchegger F, Saccavini JC, Lasser P, Elias D, Eschwege F, Parmentier C (1993) Potential contribution of 131-I-labeled monoclonal antibody in the treatment of liver metastases from colorectal carcinomas: Pretherapeutic study with dose recovery in resected tissues. Eur J Cancer 29A:1105–1111

    Article  PubMed  CAS  Google Scholar 

  • Zeng ZC, Tang ZY, Xie H, Liu KD, Lu JZ, Chai XJ, Wang GF, Yao Z, Qian JM (1993) Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb:Preliminary results. J Cancer Res Clin Oncol 119:257–259

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Schlimok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Riethmüller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Keilholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Schirrmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Wittig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K.-H. Meyer zum Büschenfelde
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Dippold
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Hämatologie/Onkologie, Martin-Luther-Universitä Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale, Deutschland

    Hans-Joachim Schmoll

  2. Klinik und Poliklinik für Innere Medizin II, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena, Deutschland

    Klaus Höffken

  3. Medizinischen Klinik II Schwerpunkt Onkologie und Hämatologie, Humboldt-Universität, Universitätsklinikum Charité, Schumannstraße 20/21, 10117, Berlin, Deutschland

    Kurt Possinger (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Heidelberg

About this chapter

Cite this chapter

Schlimok, G. et al. (1996). Immuntherapie. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79214-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79214-4_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58370-7

  • Online ISBN: 978-3-642-79214-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation